A22.0
Cutaneous anthrax
Clinical Classification Guidelines
Inclusion Terms
- Malignant carbuncle
- Malignant pustule
Medical Intelligence & Overview
Cutaneous anthrax is a bacterial infection caused by Bacillus anthracis. It primarily affects the skin, leading to distinct lesions that can progress if untreated. This condition is typically associated with exposure to infected animals or contaminated animal products. Recognized by its characteristic blister and skin ulcer, cutaneous anthrax is a significant health concern in areas where the disease is prevalent.
Causes & Symptoms
Clinical Causes: Exposure to infected animals such as cattle, sheep, or goats Handling contaminated animal products like hides, wool, or hair Contact with environmental sources contaminated with Bacillus anthracis spores
Key Symptoms: Itchy skin at the infection site Development of a raised bump resembling an insect bite Progression to a painless skin ulcer with a characteristic black center (eschar) Swelling and redness around the ulcer Possible fever and malaise in some cases
Diagnostic & Treatment
Diagnosis Path: Diagnosis of cutaneous anthrax involves clinical evaluation of skin lesions combined with laboratory testing. This may include bacterial culture from skin lesions, microscopy, or molecular methods such as PCR to detect Bacillus anthracis. A thorough occupational and exposure history aids in identifying potential sources of infection.
Treatment Protocols: Effective treatment typically includes antibiotics such as ciprofloxacin or doxycycline administered over several weeks. Management may also involve supportive skin care and, in some cases, surgical intervention to remove necrotic tissue. Early diagnosis and treatment are essential to prevent progression or systemic spread. Vaccination is available for at-risk populations but is not routinely used for the general public.
Clinical Advice & FAQs
Billing Guidance
Is A22.0 a billable ICD-10 code?
Yes, A22.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report A22.0?
Clinical documentation must specify the nature of Cutaneous anthrax and any associated comorbidities for accurate reporting.
Cite this Clinical Reference